Gregori, Ninel Z <br/><br/>
Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion.  [electronic resource] 

 -  Retina (Philadelphia, Pa.)  Oct 2008 
 - 1325-37 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1539-2864 
<br/><br/><label>Standard No.: </label>10.1097/IAE.0b013e318188501f  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Bevacizumab<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Injections<br/>Macula Lutea--drug effects<br/>Macular Edema--diagnosis<br/>Male<br/>Middle Aged<br/>Retinal Vein Occlusion--complications<br/>Retrospective Studies<br/>Time Factors<br/>Tomography, Optical Coherence<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--drug effects<br/>Vitreous Body